CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
LAIV H7N3 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01511419
NCT01511419Phase 1Completed
CompareCT.gov

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine

PATH·interventional·Posted Jan 18, 2012·Updated Apr 22, 2019

In Brief

A Phase 1 clinical trial evaluating LAIV H7N3 and placebo for Influenza and Avian Influenza. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The study hypothesis is that two doses of cold-adapted, live monovalent A/17/mallard/Netherlands/00/95 (H7N3) influenza vaccine will be safe and immunogenic in healthy adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Avian Influenza
CountriesRussia
CollaboratorsMinistry of Health, Russian Federation, Research Institute of Influenza, Russia, Institute of Experimental Medicine, Russia

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 18, 2012
Enrollment StartApr 1, 2012
Primary CompletionJun 1, 2012
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.5 years ago

Interventions

LAIV H7N3biological

2 doses of vaccine

placebobiological

2 doses of placebo